HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Cutaneous lupus erythematosus — Clinical Guidelines

Overview

Cutaneous lupus erythematosus (CLE) is an autoimmune condition characterized by skin lesions that can manifest in various forms, including discoid, subacute, and chronic variants, often triggered by ultraviolet exposure. 1 2 3 6

Diagnosis

Clinical Presentation: Malar rash, discoid plaques, nodules, comedonal lesions, and hyperpigmentation. 2 3

Histopathology: Essential for confirming diagnosis, showing features like hyperkeratosis, vacuolar degeneration, lymphocytic infiltrate, and vascular changes. 2 3

CLASI Assessment: Utilize the Cutaneous Lupus Erythematosus Disease Area and Severity Index for quantifying disease activity and severity. 5 7

Laboratory Tests: Include antinuclear antibodies (ANA) and specific anti-Ro/La antibodies, though not always positive in CLE. 1

Management

First-Line Treatments:

- Hydroxychloroquine: Effective for various inflammatory skin diseases including CLE, with a median prescription duration often exceeding 6 months. 4

Adjunctive Treatments:

- Deucravacitinib: Demonstrates superior efficacy compared to biologics and small molecules, achieving higher CLASI-50 response rates. 1 - Biologics: Litifilimab and anifrolumab show efficacy but comparative data suggest deucravacitinib as more effective. 1

Vitamin D Supplementation: Consider in patients with CLE due to prevalent vitamin D deficiency throughout the year. 6

Special Populations

Pregnancy: Specific management guidelines not detailed in provided abstracts; caution with certain medications like hydroxychloroquine is advised. 4

Elderly: No specific considerations mentioned; general management principles apply with careful monitoring of comorbidities. 4

Comorbidities: Management may need adjustment based on coexisting conditions; vitamin D status should be particularly monitored. 6

Key Recommendations

Utilize the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) for assessing disease activity and severity in CLE patients. (Evidence: Strong 5 7)

Consider hydroxychloroquine as a first-line treatment option for CLE, given its efficacy and safety profile. (Evidence: Moderate 4)

Evaluate and address vitamin D deficiency in CLE patients, given its prevalence and potential immunomodulatory benefits. (Evidence: Moderate 6)

Deucravacitinib should be prioritized over other biologics for its superior efficacy in achieving clinical response in CLE. (Evidence: Strong 1)

References

1 Bokor LA, Martyin K, Krebs M, Galajda NÁ, Meznerics FA, Szabó B et al.. Deucravacitinib shows superior efficacy and safety in cutaneous lupus erythematosus compared to various biologics and small molecules - A systematic review and meta-analysis. Autoimmunity reviews 2025. link 2 Caputo GC, Bartos CS, Pagliari C, Criado PR. Cutaneous erythematous lupus with acneiform presentation. Dermatology online journal 2023. link 3 da Silveira CSC, Lemos TB, Curty ERG, Sampaio AL, Alves MFGS, Antelo DAP et al.. Comedonic lupus, a rare variant of chronic cutaneous lupus erythematosus (CCLE): case series and literature review. International journal of dermatology 2023. link 4 Lim JW, Lee JH, Kim HJ. Use of hydroxychloroquine in dermatology: A multicenter retrospective study in Korea. The Journal of dermatology 2022. link 5 Jolly M, Kazmi N, Mikolaitis RA, Sequeira W, Block JA. Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures. Journal of the American Academy of Dermatology 2013. link 6 Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. The British journal of dermatology 2010. link 7 Krathen MS, Dunham J, Gaines E, Junkins-Hopkins J, Kim E, Kolasinski SL et al.. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis and rheumatism 2008. link

Cutaneous lupus erythematosus